CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

NDA 022410/S-014

Trade Name: **SUBOXONE**

Generic Name: **Buprenorphine Hydrochloride; Naloxone Hydrochloride**

Sponsor: **Reckitt Benckiser Pharmaceuticals, Inc.**

Approval Date: 03/12/2014

Indications: SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022410/S-014

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	
Labeling	
Summary Review	
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	
Chemistry Review(s)	**X**
Environmental Assessment	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Other Review(s)	
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022410/S-014

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 22410/S-014

APPROVAL LETTER

Reckitt Benckiser Pharmaceuticals, Inc.
Attention: Bruce Paolella
Director, Regulatory Strategy Category/ North America
10710 Midlothian Turnpike, Suite 430
Richmond VA 23235

Dear Mr. Paolella:

Please refer to your Supplemental New Drug Application (sNDA) dated and received September 20, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Suboxone® (buprenorphine HCI/ naloxone HCI) Sublingual film.

We acknowledge receipt of your amendment dated February 14, 2014.

This "Changes Being Effected in 30 Days" supplemental new drug application provides for the addition of MonoSol Rx's (b) (4) as a (b) (4) site.

We have completed our review of this supplemental new drug application, as amended. This supplement is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call LCDR Luz E Rivera, Regulatory Project Manager, at (301) 796 4013.

Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D.
Branch Chief, Branch IX,
Division of New Drug Quality Assessment III
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAMESH RAGHAVACHARI
03/12/2014

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022410/S-014

CHEMISTRY REVIEW(S)

Chemistry review #1	1. Division ONDQA HFD-170	2. NDA & Suppl. Number 22-410/SCP-014
3. Name and Address of Applicant Reckitt Benckiser Pharmaceuticals Inc. Attention: Bruce Paolella, Director, 10710 Midlothian Turnpike Suite 430, Richmond, VA 23235		4. DATE Submission PDUFA 9/20/13 3/20/14
5. Name of Drug: Suboxone	6. Nonproprietary Name: Buprenorphine/Nalaxone	
7. Supplement, CBE-30, Provides for: The addition of a (b) (4) site, MonoSol Rx's (b) (4)		8. Amendment Date
9. Pharmacological Category: Opioid dependence.	10. How Dispensed: Rx	11. Related Documents
12. Dosage Form: Sublingual	13. Potency(ies): 2/0.5 mg, 8/2 mg, 4/1 mg and 12/3 mg	

. Chemical Name and Structure:

Chemical Name for buprenorphine:

(2S)-2-[17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6α,14-ethano14α-morphinan-7α-yl]-3,3-dimethylbutan-2-ol hydrochloride.

Structure:



Chemical Name for Naloxone:

(1*S*,5*R*,13*R*,17*S*)- 10,17-dihydroxy- 4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca- 7(18),8,10-trien- 14-one

Structure:



14. Comments

The (b) (4) equipment used in the (b) (4) facilities has the same operating principle.

The (b) (4) process has been validated in the (b) (4) facility using three batches of Suboxone® (8 mg Buprenorphine/ 2 mg Naloxone) Sublingual Film manufactured in the (b) (4) facility. No changes were made to the former manufacturing process steps and the three batches were (b) (4) as approved in the NDA.

The three (b) (4) validation batches were release tested and met the registered finished product specifications.

Reckitt Benckiser Pharmaceuticals Inc. commits to present the stability data following three months accelerated and room-temperature stability storage as soon as it becomes available.

The new (b) (4) site was (b) (4) and was found acceptable based on profile. See EER below.

No changes to the specifications, manufacturing process, or controls are occurring as a result of the transfer.

15. Conclusions and Recommendations: Recommend approval.

17. Name: Review Chemist **Signature** **Date**

Bart Ho, Chemist

Branch Chief Signature Date
Ramesh Raghavachari, Ph.D.

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
SUMMARY REPORT

Application:	NDA 22410/014	**Sponsor:**	RECKITT BENCKISER
Org. Code:	170		10710 MIDLOTHIAN TPKE STE 430
Priority:	4S		RICHMOND, VA 23235
Stamp Date:	20-SEP-2013	**Brand Name:**	SUBOXONE (BUPRENORPHINE/NALOXONE SUBLIN
PDUFA Date:	20-MAR-2014	**Estab. Name:**	
Action Goal:		**Generic Name:**	
District Goal:	13-FEB-2014	**Product Number; Dosage Form; Ingredient; Strengths**	

004; FILM; NALOXONE HYDROCHLORIDE; EQ 3MG BASE
004; FILM; BUPRENORPHINE HYDROCHLORIDE; EQ 12MG BA
003; FILM; BUPRENORPHINE HYDROCHLORIDE; EQ 4MG BAS
003; FILM; NALOXONE HYDROCHLORIDE; EQ 1MG BASE
001; FILM; NALOXONE HYDROCHLORIDE; EQ .5MG BASE
001; FILM; BUPRENORPHINE HYDROCHLORIDE; EQ 2MG BAS
002; FILM; BUPRENORPHINE HYDROCHLORIDE; EQ 8MG BAS
002; FILM; NALOXONE HYDROCHLORIDE; EQ 2MG BASE

FDA Contacts:				
R. RAGHAVACHARI	Prod Qual Reviewer	(HFD-820)	3017961738
L. RIVERA	Product Quality PM		3017964013
M. SULLIVAN	Regulatory Project Mgr	(HFD-170)	3017961245
M. GAUTAM BASAK	Team Leader	(HFD-510)	3017960712

Overall Recommendation:	ACCEPTABLE	on 11-NOV-2013	by J. WILLIAMS	()	3017964196
	PENDING	on 03-OCT-2013	by EES_PROD		

Establishment:	**CFN:**	**FEI:**	(b) (4)
	MONOSOL RX LLC		
DMF No:	(b) (4)	**AADA:**	
Responsibilities:	(b) (4)		
Profile:	NOT ELSEWHERE CLASSIFIED	**OAI Status:**	NONE
Last Milestone:	OC RECOMMENDATION		
Milestone Date:	03-OCT-2013		
Decision:	ACCEPTABLE		
Reason:	BASED ON PROFILE		

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BARTHOLOME C HO
03/11/2014

RAMESH RAGHAVACHARI
03/11/2014

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022410/S-014

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 22410/S-014

CBE SUPPLEMENT – ACKNOWLEDGEMENT

Reckitt Benckiser Pharmaceuticals, Inc.
Attention: Bruce Paolella
Director, Regulatory Strategy Category/ North America
10710 Midlothian Turnpike, Suite 430
Richmond VA 23235

Dear Mr. Paolella:

We have received your Supplemental New Drug Application (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) for the following:

NDA NUMBER: 22410

SUPPLEMENT NUMBER: 014

PRODUCT NAME: Suboxone® (buprenorphine HCI/ naloxone HCI) Sublingual film

DATE OF SUBMISSION: September 20, 2013

DATE OF RECEIPT: September 20, 2013

This supplemental application, submitted as a "Changes Being Effected in 30 days" supplement, proposes the addition of a (b) (4) site.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on November 19, 2013 in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be March 20, 2014.

Cite the application number listed above at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anesthesia, Analgesia and Addiction Products
5901-B Ammendale Road
Beltsville, MD 20705-1266

All regulatory documents submitted in paper should be three-hole punched on the left side of the page and bound. The left margin should be at least three-fourths of an inch to assure text is not obscured in the fastened area. Standard paper size (8-1/2 by 11 inches) should be used; however, it may occasionally be necessary to use individual pages larger than standard paper size. Non-standard, large pages should be folded and mounted to allow the page to be opened for review without disassembling the jacket and refolded without damage when the volume is shelved. Shipping unbound documents may result in the loss of portions of the submission or an unnecessary delay in processing which could have an adverse impact on the review of the submission. For additional information, see http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/ucm073080.htm.

If you have questions, call me, at (301) 796 4013.

Sincerely,

{See appended electronic signature page}

LCDR Luz E Rivera, Psy.D.
Regulatory Project Manager
Division of New Drug Quality Assessment III
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LUZ E RIVERA
10/25/2013